Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?

Paul Lorigan; Adele Green

doi:10.1038/nrclinonc.2017.60

Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?

Paul Lorigan, Adele Green

Research output: Contribution to journal › Review article › peer-review

183 Downloads (Pure)

Abstract

Adjuvant ipilimumab is associated with an 11% improvement in 5-year overall survival in patients with high-risk melanoma, but at the cost of considerable toxicity, with half of patients discontinuing treatment owing to adverse events. An analysis of quality-of-life (QoL) outcomes, however, showed little impact of adverse effects of this treatment on QoL, which is puzzling.

Original language	English
Article number	28440331
Journal	Nature Reviews Clinical Oncology
Early online date	25 Apr 2017
DOIs	https://doi.org/10.1038/nrclinonc.2017.60
Publication status	Published - 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrclinonc.2017.60

nr Comment Nature Reviews QoL AAMAccepted author manuscript, 274 KB

Cite this

@article{ed66153628d9476f9ae900cf690b2fa5,

title = "Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?",

abstract = "Adjuvant ipilimumab is associated with an 11% improvement in 5-year overall survival in patients with high-risk melanoma, but at the cost of considerable toxicity, with half of patients discontinuing treatment owing to adverse events. An analysis of quality-of-life (QoL) outcomes, however, showed little impact of adverse effects of this treatment on QoL, which is puzzling.",

author = "Paul Lorigan and Adele Green",

year = "2017",

doi = "10.1038/nrclinonc.2017.60",

language = "English",

journal = "Nature Reviews Clinical Oncology",